维奈克拉治疗复发套细胞淋巴瘤患者结局的多中心分析
该多中心分析纳入12家美国学术医学中心81例复发套细胞淋巴瘤患者,接受维奈克拉单药(50例,62%)或联合BTK抑制剂(16例,20%)、抗CD20单抗(11例,14%)或其他活性药物。总缓解率40%,中位无进展生存期3.7个月、总生存期12.5个月;61%患者肿瘤溶解综合征低危,但12.3%仍发生TLS。
要点
- 维奈克拉单药或联合治疗复发MCL总缓解率40%,中位PFS 3.7个月、OS 12.5个月。
- 多因素分析中维奈克拉联合用药与更优OS相关,高危MIPI评分及24个月内复发/进展与更差OS相关。
- 61%患者TLS低危,但12.3%仍发生TLS,TLS仍是维奈克拉治疗MCL的重要风险。
核心结论
- 维奈克拉在高危MCL患者中产生良好总缓解率但无进展生存期短,可能在更早治疗线次和/或与其他活性药物联合中发挥更好作用。
- TLS仍是接受维奈克拉治疗的MCL患者的重要风险。
研究设计与样本
- 多中心分析,纳入12家美国学术医学中心81例接受维奈克拉治疗的复发套细胞淋巴瘤患者。
- 维奈克拉单药50例(62%),联合BTK抑制剂16例(20%),联合抗CD20单抗11例(14%),联合其他活性药物。
主要发现
- 患者高危特征包括Ki67>30%(61%)、母细胞样/多形性组织学(29%)、复杂核型(34%)、TP53改变(49%),中位既往治疗3线,91%曾接受BTK抑制剂。
- 维奈克拉单药或联合治疗总缓解率40%,中位无进展生存期3.7个月,中位总生存期12.5个月。
- 单因素分析中既往治疗≤3线与维奈克拉缓解几率更高相关。
- 多因素分析中,接受维奈克拉前高危MIPI评分及诊断后24个月内复发或进展与更差OS相关,维奈克拉联合用药与更优OS相关。
- 61%患者TLS低危,但12.3%患者发生TLS。
关键数值与推荐
- 总缓解率40%,中位无进展生存期3.7个月,中位总生存期12.5个月。
- Ki67>30%者61%,母细胞样/多形性组织学29%,复杂核型34%,TP53改变49%。
- 中位既往治疗3线,91%曾接受BTK抑制剂。
- TLS低危61%,发生TLS 12.3%。
临床怎么用
- 原文结论指出维奈克拉可能在更早治疗线次和/或与其他活性药物联合中发挥更好作用。
- 原文结论指出TLS仍是接受维奈克拉治疗的MCL患者的重要风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n = 50, 62%) or in combination with a Bruton tyrosine kinase inhibitor (BTKi) (n = 16, 20%), an anti-CD20 monoclonal antibody (n = 11, 14%), or other active agents at 12 US academic medical centers. Patients had high-risk disease features including Ki67 >30% (61%), blastoid/pleomorphic histology (29%), complex karyotype (34%), and TP53 alterations (49%), and received a median of 3 prior treatments including BTKis in 91%. Venetoclax alone or in combination resulted in an overall response rate (ORR) of 40% and median progression-free (PFS) and overall survival (OS) of 3.7 and 12.5 months, respectively. The receipt of ≤3 prior treatments was associated with higher odds of response to venetoclax in a univariable analysis. In a multivariable analysis, having a high-risk Mantle Cell Lymphoma International Prognostic Index score before receiving venetoclax and disease relapse or progression within 24 months of diagnosis were associated with inferior OS whereas the use of venetoclax in combination was associated with superior OS. Although most patients (61%) had low risk for tumor lysis syndrome (TLS), 12.3% of patients developed TLS despite the implementation of several mitigation strategies. In conclusion, venetoclax resulted in good ORR but short PFS in patients with MCL who are at high risk, and may have a better role in earlier lines of treatment and/or in conation with other active agents. TLS remains an important risk in patients with MCL who initiate treatment with venetoclax.
引用
- Sawalha Y, Goyal S, Switchenko JM, et al. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023. PMID: 36809796. doi:10.1182/bloodadvances.2022008916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。